GlassScriptPhysician profile
Jingbo Liu
NPI 1003938770
$11,610.41
in general payments reported to CMS, 2019-2025
32 companies · $2,040 in 2025
The $2,040 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,047 · 2020: $1,123 · 2021: $1,447 · 2022: $1,730 · 2023: $1,258 · 2024: $1,966 · 2025: $2,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,227 · Education: $19.31 · Gift: $17.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,226.67 |
| Education | $19.31 |
| Gift | $17.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,149.21 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,344.96 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $982.88 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amarin Pharma, INC. | $956.78 | 2019-2022 | |
| Glaxosmithkline, LLC. | $936.75 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $856.23 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $795.46 | 2019-2025 | Jardiance, Tradjenta |
| Abbvie INC. | $777.58 | 2021-2025 | |
| Pfizer INC. | $512.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $355.52 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Kowa Pharmaceuticals America, INC. | $286.88 | 2019-2025 | Zoryve, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.81 | 2024-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $191.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $166.75 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $154.31 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $143.27 | 2022 | |
| Esperion Therapeutics, INC. | $126.27 | 2021-2025 | Nexletol |
| Depuy Synthes Sales INC. | $125.00 | 2024 | Teligen |
| Janssen Pharmaceuticals, INC | $124.15 | 2019-2024 | Xarelto |
| Corcept Therapeutics | $52.11 | 2025 | Korlym |
| Astellas Pharma US INC | $47.27 | 2025 | Veozah |
| Exact Sciences Corporation | $46.65 | 2024 | Cologuard Collection Kit |
| Baxter Healthcare | $32.35 | 2023 | Hillrom - Connex Spot Monitor |
| Renalytix Ai, INC. | $24.74 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Phadia US INC. | $22.03 | 2019 | |
| Shield Therapeutics INC | $21.60 | 2025 | |
| Genentech USA, INC. | $20.59 | 2020 | |
| Linus Health, INC. | $19.45 | 2023 | |
| Nevro Corp. | $17.78 | 2021 | |
| Nabriva Therapeutics, Plc | $17.48 | 2020 | |
| Memed US, INC. | $17.18 | 2025 | Memed Bv |
| Genzyme Corporation | $16.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jingbo Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.